survey endocrinologist rais
price target
remain top diabet pick
expect annual cgm volum growth
survey result provid
increment convict intens
expect domin cgm
market long term remain
favorit way play cgm best product
pipelin industri software/analyt
us pump market seemingli acceler
growth remain clear market
leader expect
click enter text
survey us endocrinologist indic us cgm volum grow
compound-annual-growth-rate remain clear market leader intens
manag type penetr could inflect broader type adopt question
survey support pump volum growth
 gain share remain
respond expect percentag type diabet patient practic
use cgm increas today year within
year estim market penetr exit respond
expect start new patient cgm consist
forecast cgm volum post compound-annual-growth-rate
follow annual growth us type penetr
reach see clear room upsid vs compani market
broaden reimburs overal price come innov new product
libre/libr softwar solut mdi user hybrid close loop system
potenti acceler intens manag type adopt see key
driver robust volum growth
respond expect cgm penetr among intens manag type patient
increas today year year well
revis estim
among import cgm data survey view particularli
survey activ target physician serv type patient
first time type penetr approach standard care next year
market growth becom increasingli reliant intens manag type patient
data well abt success among type patient reaffirm confid
cgm market grow robustli forese futur stall materi
deceler growth next year
proport respond posit outlook use intermitt cgm
broader type patient popul continu increas within survey vast
major survey respond somewhat
posit outlook use intermitt
cgm broader type patient popul next year extrem
excit data remain earli progress within patient popul made
across mani key stakehold physician payer cgm vendor look forward
solut explicitli target patient next year type
patient us tripl number prediabet repres massiv
opportun cgm vendor
pleas see page report import disclosur
respond project cgm share grow next year
remain year libr user expect come fingerstick
respond view libr best suit intens manag type popul
market share project respond go current
year remain year share expect declin
current year expect increas current
year
also ask respond assum launch next gen system libr
end add high/low alert improv accuracy/reli near
level within scenario essenti expect split market
market share respect
ask respond prospect new entrant waveform sanvita/
lifescan nemaura data date exist player prompt us
assum materi level market share captur
increas near- long-term volum expect nearli penetr
annual due continu robust financi result well continu
strong result survey
maintain price assumpt
estim continu includ zero contribut broader type opportun
though continu believ adopt question
survey result posit demonstr remain
clear market leader exceed consensu revenu expect regardless libr
perform updates/icgm statu even arguabl worst case market share scenario
libr improv perform level continu price materi
premium still expect essenti split market
believ best product pipelin industri compani
softwar invest also pay close attent new algorithm later year
close ease-of-us gap libr like improv upon best-
in-class accuracy/reli survey data also incred posit long-term non-
intens type adopt could drive signific upsid long-term expect
near term could remain volatil due competit headlin buyer
weak top pick diabet devic increas price target
base dcf assum adopt intermitt cgm within
us non-intens type popul next year geographi
survey result posit support expect continu robust
diabet divis growth expect libr post revenu
reason momentum slow time soon penetr remain extrem low
global continu innov libr beyond ultim view
manag sale target within reason time-frame achiev
importantli beyond diabet total sale expect continu
exceed consensu expect post robust top- bottom-lin growth
mani year come
specif cgm see pump even assum lose share next
sever year expect cgm instal base growth us forese
futur ou like grow faster revenu partial off-set price headwind
compani pump franchis commerci scale support growth despit guardian
connect launch expect garner materi share stand-alone cgm diabet
total sale
respond expect percentag type patient use insulin pump increas
current next year year estim
current market penetr modestli increas type penetr well
increas type penetr see result least hsd us growth
ultim expect growth next year driven new excit product
introduct increas type adopt see
respond expect percentag intens manag type patient use
insulin pump increas current next year
well expect penetr increas exit
data encourag potenti upsid pump market growth forecast
especi survey activ target physician treat type patient
adopt yet realli materi patient popul although
recent sign improv adopt within compani result hope data sign
thing come
respond expect lose materi market share go current
year year howev expect remain clear market
leader biggest share gainer among respond go current
year year also solid result go
current year year
increas annual us type penetr forecast annual annual
volum growth forecast annual better expect close loop progress
particularli eas use and/or type adopt could drive upsid competit
dynam increas market share estim tndm/podd primarili due
recent quarterli result directli due survey data
survey result increas convict continu post above-market
growth forese futur respond indic move pharmaci
channel could materi catalyst remain enthus potenti horizon
upon launch believ combin room upsid vs consensu
expect sustain revenu growth path gross margin
signific oper margin/ep growth nearli recur revenu
horizon launch late make stock investor want subsequ
survey recent us new patient momentum modestli increas
revenu forecast increas ep
mani near term catalyst next big one probabl horizon
opportunist buyer weak throughout next month stock ytd
trade sale account dilut convert
debt expect consolid bit continu like long-term risk/
reward increas price target base dcf analysi
survey result neg still believ compani abl
post msd diabet growth forese futur also believ new product
person close loop system could reacceler growth
improv patient/physician sentiment cgm price uncertainti potenti headwind
continu robust instal base growth includ like faster ou growth keep us
confid diabet growth outlook importantli remain confid
overal compani outlook diabet repres total sale
survey result posit tandem expect compani expect
continu gain signific market share basal-iq clear winner continu
believ control-iq best system market throughout patient survey
data present ada except continu see clear upsid revenu
expect expect momentum/senti remain high stock
control-iq launch
howev note return sinc earli increas ytd
risk/reward share could becom less compel enter clear noth
survey rais concern continu rate share outperform
continu expect revenu upsid expect control-iq drive signific market
share gain still arguabl best product pipelin
pump industri sport/phon control new algorithm tri
say competit dynam valuat monitor close
compani report cowen compani
compani report cowen compani
pleas see page full market model
conduct survey endocrinologist attempt gain insight
continu glucos monitor cgm insulin pump market competit trend
survey conduct june queri respond throughout us
conduct survey qualtric note prior survey direct
accuraci market penetr competit dynam link link link
base number patient treat annual respond estim
survey reach us type popul us intens
worth note first time survey includ respond
treat intens manag type patient type patient histor
want target center experience/curr number type patient
howev given import adopt within intens manag type patient
longer term market growth decid good time aggress
target endocrinologist treat high number patient
within report defin intens manag type patient
progress multipl daili inject insulin basal bolu similar type
patient broader type patient popul type
diet/exercis oral per day insulin estim
intens manag type patient us broader type patient
anoth peopl us prediabet
note type refer intens manag patient
aim address follow key question
near long term growth outlook cgm insulin pump
market us
competit outlook cgm key vendor continu launch
new improv product
competit outlook insulin pump key vendor begin
outlook increas adopt cgm insulin pump
type patient popul next year within intens
manag type cgm broader type patient popul
averag patient per respondenttot us patient populationtyp patient us patient populationtyp cowen
believ number us cgm user increas compound-annual-growth-rate next
year exit compound-annual-growth-rate
revenu growth slightli due price headwind growth
outlook remain robust lower torrid pace expect
growth acceler launch significantli
increas eas use reduc cost patient factori calibr improv
accuraci etc acceler maintain volum growth
like us see clear upsid potenti market model
compani specif estim beyond abt/dxcm like
expect growth move forward driven continu type momentum
path standard care importantli inflect intens manag type
penetr back abt success date survey data devic
matur still plenti room improv continu
decis support solut mdi patient cost reduct
devices/softwar solut continu improv cost come continu
believ long term cgm penetr entir spectrum diabet care
includ intermitt use broader type
worth note includ contribut broader non-
intens type patient popul estim earli clear progress
made excit attention/explor payer done
arena exampl unh/dxcm pilot link link onduo progress
multipl bluecross/blueshield plan link physician sentiment per survey data
reaffirm long-term confid adopt continu believ
question
averag respond expect cgm penetr among type patient
increas today year year
line estim penetr penetr
respond expect start patient cgm
singl respond expect fewer new patient start vs
proport respond view cgm benefici type patient
insulin pump increas fourth straight survey chose cgm
survey vs survey survey
patient multipl daili inject mdi still repres us type
increas awar benefit cgm result continu robust growth
type background cowen estim estim nearli patient
type diabet us current incid grow annual us cgm
penetr among type patient exit expect
increas believ cgm becom
standard care type patient long term
type penetr estim nearli prior annual penetr
estim driven continu robust result
market penetr compani specif estim assum recent robust penetr
increas deceler survey data doesnt suggest like accordingli
see clear room upsid vs consensu expect
averag respond expect cgm penetr among intens manag
type patient increas today year
year well estim
among import cgm data survey view type
penetr approach standard care next year total cgm market
growth becom increasingli reliant intens manag type market
penetr survey well abt success among type patient
reaffirm confid cgm market grow robustli forese futur
stall materi deceler growth next year
intens manag type background cowen estim estim
patient intens manag type diabet progress
basal/bolu insulin incid grow least annual estim us
cgm penetr among patient exit expect
increas exit exit forecast penetr
increas next year revis penetr estim
higher nearli doubl previou expect survey data
suggest could room materi long-term upsid
respond estim patient begun use libr date
begin use libr next year previous use
fingerstick manag diabet come cgm
system even higher survey suggest libr user
would come fingerstick respond also view abbott libr best
suit intens manag type patient popul respond vs
choos type
support view libr continu acceler overal cgm market
growth libr better current expect upsid like
come via greater market penetr oppos lower patient number
dxcm/mdt put data context current assum us patient
use libr end patient came cgm estim
respond would patient within current model
incorpor us attrit patient total across cgm
user switch libr wont come point believ
current forecast fulli captur abt success room upsid
proport respond posit outlook use intermitt
cgm broader type patient popul next year continu
increas within survey vast major survey
respond somewhat posit
outlook use intermitt cgm broader type patient popul
next year extrem excit data context long-term broader
type penetr outlook remain earli progress within patient popul
made across mani key stakehold physician payer cgm vendor look
forward solut explicitli target patient next year
still incorpor broader us type patient popul within market
estim though continu strong convict adopt within
popul question us type patient
tripl number peopl us prediabet massiv opportun
could drive signific long-term growth
abt libr tremend success first year us launch
robust momentum show sign materi deceler ahead libr
expect abt market share grow current next
year remain year current libr us market share
forecast expect libr exit market share volum
increas year long term ask assum scenario
libr accuraci near level respond expect abt market share
increas year year long-
term forecast think delta primarili due respond higher
baselin patient also worth note respond expect
essenti split market year consist market
import reiter respond us expect vast major
libr user transit fingerstick oppos real time cgm
system accordingli expect libr continu help drive overal market growth
cgm awar long-term benefit vendor particularli true among
type patient libr strong success date libr patient base
per manag respond believ libr best suit
respond expect remain cgm market leader
forese futur regardless libr perform improv respond
expect share declin current year remain
year magnitud share declin similar long-term
market share forecast estim us share declin exit
worth note believ room
upsid forecast accordingli baselin market share could higher
month
ask assum libr improv perform near level
respond expect market share declin year
year essenti line expect current
expect similar believ due higher proport
user broader market among respond regardless view
near worst-cas market share scenario account price
reduct time didnt ask respond assum chang
price time dxcm best-in-class product pipelin mdi decis
respond expect continu lose market share next year
expect share within patient declin current
year year within previous describ libr
scenario near accuraci expect share year
year better expect though start much higher base
survey popul expect market share declin
exit long term expect mdt cgm market
posit remain base integr pump system next year
launch first us stand-alone cgm guardian connect howev
indic product much success us simpli put
behind competitor accuracy/reli eas use dont expect chang
near medium term clear despit outlook market share declin
still expect signific patient volum growth estim
annual us cgm instal base growth next year
senseon rate launch implant cgm us late
respond result didnt suggest materi disrupt current incumb
abt/dxcm/mdt though result much better survey
respond expect market share increas current
year year essenti line forecast still earli
execut long-term product pipelin extend wear reduc
calibr compani clearli opportun carv small nich
market
note player expect enter market see
page full list current/futur vendor includ agamatrix/waveform
sanvita/lifescan other possibl competitor launch materi price
discount current real time cgm price around libr struggl
see els product differenti themselves/attempt grab market
share howev data date exist prompt us includ
materi market share prospect new entrant set high
bar move higher pipelin product launch
respond expect pump penetr among type patient continu
modestli increas current next year
cowen outlook estim compani data suggest us pump market
acceler unless lose far share believ
increas estim annual us type pump penetr next year
annual expect overal market growth
hsd forecast assum type penetr increas exit
next year close loop
system progress faster expect particularli eas use/simpl and/or
type market penetr acceler possibl upsid forecast
respond expect pump penetr among intens manag type
patient increas materi current median
next year median increas past month
averag median flat y/i
encourag data especi consid survey activ
target physician treat type patient given data recent encourag
trend increas type pump penetr forecast
forecast assum penetr increas
year adopt begin materi
could repres clear upsid driver overal pump market growth
respond expect remain pump market leader though lose
materi share declin current year year
tandem share expect increas significantli current
year year greatest expect increas among vendor insulet
also solid result market share expect increas current
year year
cowen estim outlook respond estim slightli better
slightli wors current forecast next year
expect market share declin exit
increas increas
key stem market share loss new product expect
launch april manag target promis time rang
continu less optimist commerci success futur system
ultim difficult compet eas use/simpl vs peer less
accurate/reli sensor requir calibr cgm improv critic
improv competit mdt autom insulin deliveri system
pipelin target inspir confid close match
excit continu build ahead control-iq launch later
year remind control-iq hybrid close loop system launch
partnership dxcm/typezero includ basal rate modul high
low blood glucos level well autom correct bolus worth note
compani also full pipelin behind control-iq sport/phon control
like new autom insulin deliveri algorithm possibl
market share gain begin moder subsequ anima tailwind
expir competit aid launch though risk least month away
meantim control-iq drive revenue/new patient upsid
significantli increas market share forecast due robust result past
month competit system dont launch current commun timelin
possibl forecast remain low
fare well survey especi consid product
market today without autom insulin deliveri featur improv
access/declin up-front cost see importantli horizon launch
posit well continu grow market growth rate
forese futur see potenti clear upsid forecast
arguabl biggest beneficiari acceler penetr new patient
start mdi offer uniqu valu proposit patients/physician
increas use pharmaci channel zero hardwar up-front cost
huge differenti rapidli expand market access acceler
instal base growth today even launch horizon
materi catalyst compani
worth note multipl new competitor expect launch next
year see page full list entrants/pipelin includ beta bionic bigfoot
biomed potenti other focus pump delay still
possibl roch diabeloop eoflow etc earli know
prospect competitor materi disrupt market though clear
rel benign competit environ past year like
respond excit potenti hybrid close loop fulli
close loop system though worth note data modestli weaker vs
survey respond expect cgm-autom system drive
inflect type pump penetr vs survey anoth
repli mayb vs possibl earli experi turn
physician
understand excit new system next year could
repres materi market catalyst control-iq patient feedback data except
data far also suggest market truli acceler howev
import note biggest barrier broader pump penetr cite
physician cost complex unlik address first gener
system anyth seem possibl first gener system may increas cost
complex certainli also worth note respond didnt
includ inflect penetr forecast instead call continu modest
annual increas clear potenti acceler penetr driven
close loop system earli data suggest market acceler could play
speak final long-term verdict still
respond expect decis support solut mdi patient
repres long-term headwind pump adopt anoth say mayb
earli major player expect launch smart pen/decis support
solut next month dxcm/nv other may keep pump
penetr reach long term forecast howev addit
option mdi patient much lower cost full aid clear risk
increas access patient move pharmaci channel appear like
materi catalyst podd new patient start respond expect medicar
coverag drive increas number patient choos omnipod
respond expect recommend omnipod often due avail
pharmaci benefit catalyst help sustain well
market growth horizon launch late
survey result posit market share estim respond
slightli current expect though still impli continu market share
gain robust revenu growth expect libr revenu
room still signific futur revenu growth offset like continu
declin abt fingerstick busi ultim view manag target
libr revenu within reason time-frame achiev
also expect number posit develop next month includ
launch libr commerci launch abt first insulin deliveri partner
bigfoot biomed specif libr continu expect approv
point next month icgm design accordingli expect
signific improv perform albeit like quit level stay tune
fda data set importantli real world patient/physician feedback wed
focu particularli outlier hypo perform alert accuraci regardless
least partial close gap perform potenti
posit success compet custom util autom insulin
deliveri system long term albeit like near medium term
despit robust growth date remain earli day libr us type penetr
exit us intens manag type penetr
intern market far less penetr expect abbott diabet divis
post robust growth forese futur diabet repres
survey result posit continu take share near
term compani convert tremend amount fingerstick user interstiti
monitor outsiz share gain moder beyond
pois remain clear market leader togeth forese
futur view best product pipelin industri accordingli
favorit way play year secular growth theme data regard type
adopt intens manag non-intens particularli encourag
provid confid cgm market continu post robust growth
next year prime beneficiari
two biggest area pushback bear stock libr
share loss price expect
start libr view nearli worst case scenario market share
libr improv perform level remain price signific
premium respond still expect retain market share
next year essenti split market
essenti floor dont believ give adequ credit
best-in-class pipelin like elimin eas use advantag libr
possess today fulli dispos slimmer bodi footprint retain like
improv upon best-in-class accuracy/reli also believ
make right softwar invest differenti long term decis
support softwar launch next month like provid visibl
front addit control-iq launch driven
also import note base manag commentari abl
compet success profit wherev market goe price suggest
reason gross margin possibl scale libr price today
us bring us next point
price come via unfavor mix chang ou proactiv move
pharmaci channel durabl discount select instanc current
forecast annual revenu per patient declin
would impli year still price premium libr
albeit rel immateri differ pocket cost patient less
annual could prove optimist especi libr success achiev level
perform ad alert yet determin believ
unlik howev also believ possibl maintain price premium
via softwar offer patient decis support solut autom
importantli think stock bear case predic downsid price scenario
consist overst instanc price pariti libr
believ instal base forecast would far low mostli offset revenu
shortfal associ price demonstr clear demand elast
market price line wed also expect dxcm
market share much higher current forecast downsid price
scenario overal market penetr dxcm market share would like
get back near- long-term stock outlook remain top pick
diabet space libr headlin could drive volatil near term think
well posit materi exceed consensu revenu
expect regardless libr icgm status/perform improv
importantli vast under-penetrated market best product
pipelin industri softwar invest also would keep close
eye improv manag commentari suggest potenti under-
the-radar perform improv later year via algorithm updat
expect remain clear market leader cgm forese futur
ultim expect cgm penetr entir spectrum diabet care long
term broader type prediabet view broader type adopt question
survey provid increas convict long term penetr
non-intens type opportun increas price target
base dcf analysi repres sale sale
p/fcf
survey mostli neg respond expect lose market
share across pump cgm anima tailwind expect ceas
late new product competit dynam becom primari driver
revenu growth expect continu grow busi via favor
end market dynam cgm pump market growth us ou increas cgm
attach expect remain pump market leader seem like
lose market share grow broader market growth rate forese
someth expect long time entir due compani
inferior cgm vs competitor compani histor built domin pump
market share via two primari differenti biggest commerci infrastructur
signific margin compani offer integrated/autom
cgm/pump system still largest infrastructur import
advantag cgm integr longer uniqu especi ultim
pursu announc make product interoper non-mdt
could protect pump revenu though diminish cgm revenu long term
howev worth note achiev outcom data manag
target significantli improv patient experi vs via less
calibr fals alert respond market share loss forecast would
like pessimist also set outcom target person
close loop system would best-in-class upon launch though target
appear bit ambiti us link time rang increas vs
without meal announc help control post meal glucos spike
feel use promis futur product way drive near
term sale lock custom anoth renew cycl
view import mdt near long-term competit cgm
perform eas use improv manag laid full cgm
product pipelin next sever year link repres signific
progress vs current guardian system still clearli behind dxcm/abt
commentari compani ada analyst event didnt inspir confid
util core sensor chemistri guardian also worth note
unlik immun cgm market price pressur next year although
still expect us cgm instal base growth higher ou
off-set pricing/competit pressur
despit competit pressur continu believ
abl post growth diabet divis long term via favor end market
growth cgm pump ou higher us higher cgm attach rate
current forecast msd growth next year diabet repres
view survey result posit support expect
continu gain market share forese futur increas
access/th pharmaci channel provid catalyst market growth late
horizon launch respond market share forecast posit
especi specif type also encourag respond expect
medicar coverag access pharmaci channel catalyz increas
new patient start current model insulet global diabet revenu grow
compound-annual-growth-rate next year see clear upsid potenti forecast driven
pharmaci channel horizon intern expans
move pharmaci channel significantli reduc up-front cost
patient free remind cost cite biggest headwind pump
adopt everi survey weve done reduc oper expens long term
transit major patient base increas annual revenu per
patient time remind manag expect off-set loss
revenu go away long term anyway move phone control
increas pod price occur first year transit still
clear minor us instal base pharmaci estim
averag throughout accordingli higher proport instal
base transit pharmaci channel higher pod price us revenu growth
outpac us instal base growth beyond
importantli continu believ horizon incred
differenti system upon launch late given podd uniqu form factor
could one system capabl elimin devic patient near
medium term requir phone cgm pod tndm sport could
well requir infus set await robust clinic data earli data
solid encourag frequent manag emphas
eas use throughout develop process well broad studi young
pediatr horizon robust catalyst diabet busi
lastli intern expans clear catalyst upsid vs diabet
forecast current model ou revenu growth forese futur
could achiev growth exist market grow
underli rate mid-teen low like begin
expand new geographi start europ move beyond
expect ultim exceed long term revenu forecast
stock ytd trade sale adjust
convert think could consolid littl continu
like long term risk/reward sustain revenu growth strong
diabet partial off-set drug deliveri weak gross margin robust
oper margin/ep growth nearli recur revenu attract
fundament compani continu increas valu long term
also clear neg catalyst next month outlook
continu upsid vs consensu expect excit horizon launch
increas price target modestli increas
survey result posit tandem expect compani
expect continu gain signific market share consist prior survey
basal-iq clear winner continu believ control-iq best system
market throughout patient survey data present ada
except continu see clear upsid revenu expect expect
momentum/senti remain high stock control-iq launch
howev possibl return sinc earli run ytd
risk/reward stock becom less compel enter control-iq result
strong though anima tailwind begin fade investor
point like begin worri new upcom competit launch
beta bionic bigfoot etc also worth note consensu estim
increas revenu sinc begin year still
path upsid though far convict revenu upsid
clear noth survey rais concern perhap
overst potenti sentiment chang still arguabl
excit pipelin among pump vendor sport/phon control set launch
new algorithm togeth dxcm/typezero like launch
also still signific room market share gain us
market today much lower intern remain possibl low
futur market share gain especi new product disappoint
delay new competitor arent disrupt continu believ stock
worth base dcf analysi downsid like wors
stick continu rate share outperform
ask benefici type patient glycem control
hypoglycemia patient qualiti life insulin pump cgm respond
chose cgm chose pump respond choos cgm
survey respond respond
awar benefit cgm clearli grow although wed argu
room significantli growth expect trend continu
forese futur believ data along data survey
demonstr cgm penetr much higher today
figur could choos one cgm insulin pump devic believ
benefici type diabet patient glycem control hypoglycemia patient qualiti
averag respond expect penetr type patient increas
today year year repres steadi
level signific increas worth note data skew outlier
median expect penetr year also note
penetr within respond market estim us penetr
exit henc may posit bia within survey
direct posit
also encourag respond expect start new patient
cgm/fgm vs expect add singl
respond expect new patient add declin vs
figur expect start patient cgm/fgm
figur proport type patient current use
cgm expect next
month thesamey moderatelymor cowen
averag respond expect cgm penetr intens manag type
patient increas today year year
note respond current broader market averag
estim cgm penetr among us intens manag type patient
exit reach exit
view result particularli noteworthi given respond longer
practic primarili serv type patient importantli level expect
penetr year well current expect current
forecast us intens manag type penetr reach
us type penetr approach next year adopt among
intens manag type patient becom increasingli import broader
market growth import trend monitor key catalyst includ
reimburs real time cgm use privat coverag increas new product
smart pens/decis support tool reduc cost
figur proport type patient intens insulin regimen current use
cgm expect next year
ask statement describ view use intermitt cgm
broader type patient popul next year proport
respond chose somewhat posit aggreg
survey signific increas proport
respond choos posit
remain incred earli believ data reinforc view long term
intermitt cgm becom part standard care broader type
patient popul potenti prediabet
multipl catalyst upcom next year potenti
begin increas adopt intermitt cgm use among broader non-insulin use
type patient includ new product softwar etc like heavi
commerci invest dexcom/verili abbott well third
parti compani util glucos monitor technolog within manag
solut onduo virta omada livongo etc use fingerstick today expect
most/al migrat cgm time
also worth note clear interest payer find new solut
manag insulin use type patient patient popul signific cost
often comorbid clear exampl program conduct
multipl bluecross/blueshield plan work onduo link like
expand sinc among other
figur statement best describ view use intermitt cgm broader
type patient popul next year
respond said will recommend/prescrib cgm
patient technolog avail pharmaci channel oppos
dme durabl medic equip data back survey data present
analyst day well abbott overal commerci strategi note
physician would increas cgm prescript pharmaci benefit need
certif medic necess dme channel oppos
figur cgm elig pharmaci benefit oppos reimburs durabl
medic equip dme impact willing recommend/prescrib cgm
remind shift pharmaci channel dme durabl medic
equip expect net posit nearli everi key stakehold patient
physician cgm vendor payer lone except dme-specif distributor
patient averag pharmaci channel offer easier access far less
paperwork/hurdl dme case lower pocket cost
physician provid easier path get patient access technolog
easier write prescript help patient dme paperwork stay
cgm
cgm vendor offer expand access technolog scale
reduc opex requir patient support dme channel requir back offic support
help patient onboard paperwork/renewals/app payer
lastli payer reduc averag cost cgm vendor
accept lower price order facilit pharmaci access
significantli less cgm less cgm cgm cgm cowen
consist prior expect libr like continu gain market share
next year primarili via convers fingerstick user cgm see page
data sourc new libr user howev pace libr share gain
like moder vs past year expect robust first year
market post us launch expect remain market leader
forese futur given best class pipelin softwar advanc etc
assess futur market share expect ask respond assum
abbott launch new version libr high/low alert end
launch fulli dispos miniatur sensor end
backdrop respond expect proport patient use
libr increas today next year
expect lose share next year interestingli
expect lose share beyond next year current estim
total us share loss
expect lose market share among respond patient
next year anoth year
senseon expect gain market share next year grow
total market next year
figur proport patient activ use cgm use follow system pleas assum follow end
abbott launch next gener version libr includ high/low alert end
launch dispos transmitt miniatur sensor
also ask respond hypothet assum addit high/low
alert abbott next gener libr product also improv accuracy/reli
near level didnt ask respond assum price come
accordingli nearli worst-cas market share scenario
present scenario respond note wouldnt
chang prior market share expect averag data among
share expect assum libr improv
accuracy/reli near level year
share expect assum libr improv
accuracy/reli near level year
clearli data posit abbott libr like significantli improv
perform howev think notabl scenario respond still
expect dxcm market share lower libr isnt
accurate/reli view suggest abl
achieve/potenti exceed consensu revenu expect regardless ultim libr
approv time and/or perform without factor
respond expect vast major patient use libr
previous use fingerstick remaind come compet
cgm system even higher last survey fingerstick
reiter view libr success grow pie take other
upsid current libr adopt expect like come
higher market penetr lower result dxcm/other
figur proport exist futur libr user believ previous
use follow glucos measur
consist histor survey work ask patient popul libr
best suit intens manag type patient option chosen often
interestingli even survey
figur patient popul believ abbott libr best suit check
fingerstickscom rtcgm basal bolu insulintyp basal insulin onlytyp non-insulin cowen
first time year weve conduct survey accuraci
number one choic among respond factor drive cgm choic eas use
respond histor alway top follow cost
accuraci
possibl inclus physician care much greater number
intens manag type patient type patient influenc result first
time histori survey howev worth note eas use still
number chosen respons among respond care type patient
type although accuraci slightli behind eas use
respond vs greater prefer eas use overal data
collect made respond
figur import factor drive patient choic cgm/fgm
view result posit accur
product market abbott like simple/easi use current
howev import note eas use advantag potenti cost
advantag libr vs like elimin launch
late
also expect wide view accur sensor market
consist fda clinic data sensor like significantli
improv perform libr although import rememb isnt
stand still either enhanc like improv perform
figur cgm system believ accurate/reli today
factor drive recommend respondentseas requir lack insulin support phone app profil accurate/reli cgm respondentsdexcom guardian cowen
respond expect pump penetr among type patient continu
increas steadili next year averag increas
today year
believ respond nation averag us pump penetr
estim penetr current approxim us type patient
current forecast penetr increas exit exit
long term forecast year
figur proport type patient current use insulin pump
expect year
respond expect pump penetr acceler among intens
manag type patient grow today next
year increas past year averag acceler
widespread across respond skew averag demonstr
data median respons
view result particularli encourag given survey activ
target physician treat primarili type patient includ
progress basal/bolu insulin intens manag
believ respond nation averag us intens manag
type penetr estim current penetr expect
increas penetr within patient
popul acceler respond expect could drive overal us pump
market growth mid teen vs current forecast high singl digit low
figur proport intens manag type patient current use
insulin pump expect year
optim slightli temper vs major respond
still expect first gener hybrid close loop system drive inflect
penetr pump among type patient next year anoth
repli mayb respond said ask system
excit chosen far often y/i chosen less often
y/i though still often chosen system
figur believ launch first gener hybrid close
loop/clos loop system drive inflect
penetr pump among type patient next
figur cgm-autom insulin deliveri platform
excit check appli
perhap temper optim explain y/i chang
barrier pump adopt exist sever year remain
complex pump barrier date address close loop
system anyth increas believ time compani
develop solut focu simplic patient caregiv
success hope system launch accomplish
figur believ import barrier put type patient
pump check appli
anticip aid bionic respondentsmost import barrier respondentsout pocket close loop insulin dose support system readi proper pump training/support effect reliabl cgm cowen
addit tradit barrier pump adopt possibl new solut
mdi user temper long-term penetr outlook particularli type
specif combin bluetooth enabl insulin pen cgm decis
support softwar potenti help mdi user achiev much better overal
outcom cost patient much full autom insulin deliveri
system albeit like wors outcom metric
respond view decis support solut best suit intens
manag type patient although nearli mani respons type
say definit wont repres headwind long-term pump
adopt expect repres headwind mayb
figur number compani develop decis support
system insulin pen user compris smart pen
bluetooth enabl cgm softwar translat data
action treatment recommend patient
patient popul believ decis
support system best suit
figur believ decis support system launch
insulin pen user repres headwind longer term
multipl vendor expect provid decis support solut mdi
patient next year includ major insulin manufactur nv like use
softwar use softwar cgm sni unclear although
like invest cgm vendor dxcm/typezero sugar iq via
bigfoot pure play hardware/softwar vendor companion medic glooko
time expect major insulin manufactur partner domin
market given domin market share insulin manufactur control pen
across type type next page patient market leader expect
lose materi market share next year though remain clear market
leader manag remain enthus expect launch april
reinvigor mdt competit outlook time tell
respond expect gain share next year
continu robust share gain past month basal-iq help gain
market share respond clearli expect control-iq launch sustain
acceler tndm recent strong momentum
respond expect gain market share across type especi type
patient see next page expect achiev despit vendor
market next month without cgm-autom well
rel less signific anima tailwind competitor
execut horizon could clearli upsid respond long-term
figur proport type pumper current use follow product expect year
check kol continu suggest product design type patient
mind focu simplicity/eas use best posit among
patient popul long term potenti smart pens/decis support
howev tradit type vendor continu domin still nascent
penetr market respond expect continu next
year expect gain notabl market share expect
remain market leader
interest see market evolv next year multipl
new competit solut come market includ patch pump mayb though
recent delay like target product
solutions/advertis patient popul decis support tool via
figur proport type patient activ use pump use follow product expect year
estim us type patient within medicar prior
commerci insulin pump without medicar coverag broad
part coverag realli implement earli also worth note
recent medicar coverag help expand medicaid coverag move
survey data medicar coverag respond expect higher
proport patient use omnipod
figur insulet/omnipod offici gain medicar coverag expect medicar
coverag significantli impact proport type pumper use
insulet/omnipod next year
perhap importantli podd decis shift commerci distribut
pharmaci channel away dme could repres signific catalyst/differenti
compani remind use launch dash system
facilit shift offer patient dash free off-set higher pod
price per payer contract reduc up-front cost potenti lower pocket
cost patient could help gain market share/acceler new patient start
respond believ shift pharmaci could make like
recommend omnipod patient
figur insulet/omnipod increasingli available/reimburs pharmaci benefit instead
durabl medic equip avail pharmaci effect
willing recommend omnipod patient
morey morey morey morey moreno less like recommend like recommend like recommend cowen
 announc earli compani would explor strateg
altern anima busi octob decis made
offici exit pump busi us canada chosen
partner provid transit patient provid anima suppli
patient septemb upon time anima suppli longer
avail given arrang like vast major anima user
convert differ pump end late anima like
patient use pump us slightli less total market share
first crack anima patient come warranti base
data date appear like compani convert anima user
been/wil like continu second biggest beneficiari compani
clearli greatest winner rel initi expect note base
manag commentari low us new patient shipment anima user
sinc like ultim convert
also benefit though seemingli smaller degre peer
figur j/anima process exit insulin pump busi patient
histor use anima pump current use anima proport
believ chosen/wil choos follow pump
pen cowen
compani report cowen compani
companyproductcommerci timelinesdistinguish enhanc late possibl improv outlier perform day perform reduc warm time late earli broad roll-out tbd decis support systemsmedtronicnon-adjunct guardian stand-alone us april fda submiss impli fda submiss like late earli reduct fingerstick vs guardian expect meet icgm criteria synergyu fda submiss impli late earli submiss like mid late launch fulli dispos volum reduct new step insert still expect requir day calibr abbottlibr fda submiss januari expect approv launch octob termtbasenseonicseversens dayu clinic trial expect run like launch ou launch dayus/ tbdextend wear day us/ou tbdagamatrix waveform cascadeu expect launchou expect late launchlifescan/nova biomedicaltbdu tbdou earli cgmu tbdou launch tbdou select market launch submit fda seemingli launch ou launch august icgm systemus/ tbdimplant sensor extern receiv year sensor life like requir calibr bit bulki continu glucos monitor cgm product pipelin tracker dispos miniatur lower cost mayb day wear like perform improv reduc calibr one day unclear mani thereaft insulin dose claim like enabl reimburs geograph specif commentari like launch along insulin pen partner lilli novo etc start late earli term flash capabl batteri incorpor sensor remov transmitt addit analytesnon-invas cgm patch skin electr current draw glucos skin report strong accuraci metric although data appear like replic real world skeptic given challeng non-invas monitor intern work aid typezero acquisit action treatment recommend mdi user core featur current libr factori calibr day wear trend data plu alerts/alarm still requir interrog sensor glucos data like materi perform improv base icgm commentari data present ada made clear much pipelin includ addit analyt beyond glucos solid accuracy/reli per clinic trial data physician check product still requir calibr non-adjunct claim like inferior accuraci requir calibr seemingli shorter wear time limit detail date technolog acquir isens earli seemingli current market leader despit inclus calibr data shown accuraci peer eas use inferior leader requir calibr long term market viabil unclear pend improv cowen
compani report cowen compani
productcommerci timelinesdistinguish target april launchou tbd person close loop us fda submiss impli late earli submiss like mid late launch ou tbdhorizonu launchou tbdloopu observ studi on-going time suggest late launch possibl ou expect launch tandembasal-iqu launch august low glucos suspend impress clinic import usabl data ou launchcontrol-iqu launch ou launcht sportu pump screen phone control bolu button devic integr cgm control-iq algorithm ou tbdtidepoolloopu observ studi conclud bionicsilet insulin onlyu earli launch pivot expect initi tbdilet dual hormoneu launch like year post insulin launch ou tbdbigfoot biomedicalloopu like inject bigfoot smart pen/dss like launch pivot trial time disclos pump hardwar asant abbott cgm bigfoot autom insulin deliveri algorithm limit clinic data date also plan consolid prescript like except insulin eli lillyhybrid close loop commerci name yet disclos us/ou like launch insulin pen launch launch screen durabl pump pre-fil insulin cartridg close loop develop timelin tbd us expect ou alreadi launch us tbdothersroch eoflow sfc fluidic inreda cambridgetbdinsulin version util either cgm clinic data date solid tir focus simplic throughout user oper requir patient weight start small medium larg meal input somewhat near commerci dual-hormon system develop util glucagon zealand theoret reduc sever hypoglycemia risk iphon app like approv part fda interoper initi new algorithm class similar icgm/ac pump current offici partner app resid patient smartphon disk shape pump design deka cgm clinic data share date hybrid close loop run android control current use kaleido pump though explor option cgm predict algorithm modul suspend basal insulin deliveri cgm also autom correct bolus clinic data tir minim time hypo perhap importantli patient feedback data tir smartphon control meal predict although limit detail safeti protocol loop algorithm do-it-yourself commun taken fda tidepool compat icgm ace pump sign partner insulin pump product pipelin tir target includ correct bolus waterproof expect time close loop close loop smartphon control earli time rang data amongst broad subset patient includ young pede encourag cowen
cowen compani
market overviewtot diabet diagnos ensiv ensiv insulin growth type manag type mng type type diabet diagnos total diagnos insulin penetr growth adult total pumper penetr growth pediatr total pumper growth depend type inject multipl per type insulin ensiv insulin growth total pumper ensiv manag diabet devic market model insulin deliveri cowen
cowen compani
markettot market user period growth intens manag exist renew patient instal base share vendortot exit market septemb bionic bigfoot biomed othersu diabet devic market model insulin share cowen
cowen compani
market overviewtot diabet diagnos ensiv total cgm ensiv insulin growth cgm cgm type manag type cgm mng type diabet diagnos total diagnos glucos monitor penetr total total cgm growth cgm inject multipl per day continu glucos monitor penetr mdi type cgm user continu glucos monitor penetr type cgm user ensiv manag type total type ensiv insulin segment growth cgm inject multipl per day mdi cgm penetr type cgm user insulin cgm penetr type cgm user us diabet devic market model glucos monitor cowen
cowen compani
marketcgm userstot cgm user period assum zero contribut fromgrowth insulin use patient drive signific upsid long intens manag forecast patient share entri waveform like other ltpatient abbott- /other- us diabet devic market model continu glucos monitor share cowen
compani report thomson eikon cowen compani
mm except profit flat y/i due scale new facil re-affirmed target previous oper y/i msd oper margin target mid-teensincrement non-oper expens interest major interest expens non-cashearn per except per share gross op consensu estim cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
